Competitor Analysis Interferon
Product description
TThe Competitive Intelligence Report Interferon as of February 2011 provides a competitor analysis in the development pipeline of novel recombinant and natural interferon alpha, beta, gamma and of other subtypes for treatment of infectious diseases, cancer and multiple sclerosis, respectively.
Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report provides information on the marketed interferon preparations and includes a compilation of current active projects in research and development of novel interferon products including novel presentation or delivery formats. In addition, the report lists company-specific product portfolios and R&D pipelines of interferon products. Competitor projects are listed in a tabular format providing information on:
Interferon alpha:
Other Interferons
Interferons delivered by DNA
Interferons as part of Vaccines
About La Merie
Corporate Interferon Product Portfolios and R&D Pipelines:
TThe Competitive Intelligence Report Interferon as of February 2011 provides a competitor analysis in the development pipeline of novel recombinant and natural interferon alpha, beta, gamma and of other subtypes for treatment of infectious diseases, cancer and multiple sclerosis, respectively.
Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report provides information on the marketed interferon preparations and includes a compilation of current active projects in research and development of novel interferon products including novel presentation or delivery formats. In addition, the report lists company-specific product portfolios and R&D pipelines of interferon products. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Interferon alpha:
- 1st generation Interferon (IFN) alpha-2a
- 1st generation IFN alpha-2a biosmilars and off-patent country products
- 2nd generation IFN alpha-2a
- 2nd generation IFN alpha-2a biosimilars and off-patent country products
- 1st generation IFN alpha-2b
- 1st generation IFN alpha-2b biosimilars and off-patent country products
- 2nd generation IFN alpha-2b
- 2nd generation IFN alpha-2b biosimilars and off-patent country products
- New developments of IFN alpha-2b
- Other IFN alpha subtypes
- IFN alpha with not-specified subtype
- 1st generation IFN beta-1a
- 1st generation IFN beta-1a biosimilars and off-patent country products
- 1st generation IFN beta-1b
- 1st generation IFN beta-1b biosimilars and off-patent country products
- Next generation IFN beta
- Other IFN beta products
- IFN beta products with not-specified subtype
Other Interferons
Interferons delivered by DNA
Interferons as part of Vaccines
About La Merie
Corporate Interferon Product Portfolios and R&D Pipelines:
- Advanced Protein Technologies
- Alfa Wassermann
- Alios Biopharma
- ALLOZYNE
- AlphaRx
- Amarillo Biosciences
- Ambrx
- Amega Biotech
- Anhui Anke Biotechnology
- Ascendis Pharma
- Astellas Pharma
- Asubio Pharma
- Axxo
- Bayer Schering Pharma
- Beijing Tri-Prime Genetic Engineering
- Berlex
- Bio Sidus / Sidus
- Bio-Manguinhos
- Biogen Idec
- BioGeneric Pharma
- Biolex
- BioPartners
- Bolder BioTechnology
- Bristol-Myers Squibb (BMS)
- Celgene
- CinnaGen
- CJ Corporation
- Cyplasin Biomedical
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Development Center for Biotechnology (DCB)
- Digna Biotech
- Dong-A Pharmaceutical
- DSM BioSolutions
- Faron Pharmaceuticals
- Flamel Technologies
- Genexine Co
- Green Cross
- Guangxi Beisheng Pharma
- HanAll Pharmaceutical
- Hanmi Pharmaceutical
- Hayashibara
- Heber Biotec
- Helix BioPharma
- Hemispherx
- Ichor Medical Systems
- Index Pharmaceuticals
- InSight Biopharmaceuticals
- Intarcia Therapeutics
- Intas Pharmaceuticals
- InterMune
- Kee PharmaLG Life Science
- Lipoxen
- Lupin Pharmaceuticals
- Maruho Pharmaceutical Co.
- Medgenics
- Medtronic
- Merck & Co.
- Merck Serono
- Mochida Pharmaceuticals
- MolMed
- Nanogen Biopharmaceutical
- Novartis
- Nuron Biotech
- Otsuka Pharmaceutical Co
- PBL Therapeutics
- Phage Pharmaceuticals
- PharmaEssentia
- PolyTherics Limited
- Probiomed
- PROLOR Biotech
- Proxima Concepts
- Reliance Life Sciences
- Rentschler Biotechnologie
- Rhein-Minapharm Biogenetics
- Roche
- SciGen
- ScinoPharm Biotech
- Shantha Biotechnics
- Shenyang Sunshine Pharmaceutical Corporation
- Shenzhen Neptunus Interlong Bio-technique Company (“Interlong”)
- Sicor Biotech UAB
- Sudershan Biotech
- Swedish Orphan Biovitrum
- Synairgen
- Teva Pharmaceutical Industries
- Therapeutic Proteins Inc
- Three Rivers Pharmaceuticals
- Tinajin Hualida Biotechnology
- Toray
- Transgene Biotek
- Trigon Biotechnological
- USV Ltd.
- Vakzine Projekt Management
- Venturepharm
- Virax Holdings
- Wockhardt
- Xiamen Amoytop Biotech
- Zenotech Laboratories
